D. E. Shaw & Co., Inc. Cullinan Oncology, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CGEM
# of Institutions
140Shares Held
65.9MCall Options Held
77.2KPut Options Held
15.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$125 Million21.42% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$94 Million3.07% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$58 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$55.8 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$53.6 Million1.2% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $745M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...